With 1.08 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.28 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $2.34 whereas the lowest price it dropped to was $2.21. The 52-week range on NLSP shows that it touched its highest point at $15.59 and its lowest point at $1.30 during that stretch. It currently has a 1-year price target of $160.00. Beta for the stock currently stands at 0.17.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of NLSP was up-trending over the past week, with a rise of 0.45%, but this was down by -0.88% over a month. Three-month performance surged to 50.00% while six-month performance rose 10.84%. The stock gained 6.64% in the past year, while it has lost -72.56% so far this year.
Float and Shares Shorts:
At present, 3.16 million NLSP shares are outstanding with a float of 2.27 million shares on hand for trading. On 2025-06-13, short shares totaled 72299.0, which was 147.0 higher than short shares on 1747267200. In addition to Mr. Alexander Zwyer M.B.A. as the firm’s Co-Founder, CEO & Director, Dr. Eric Konofal M.D., Ph.D. serves as its Co-Founder & Chief Scientific Officer.
Institutional Ownership:
Through their ownership of 0.100389995 of NLSP’s outstanding shares, institutional investors have minority control over the company.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for NLSP since 2 analysts follow the stock currently. There are 2 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$1.6 being high and -$1.6 being low. For NLSP, this leads to a yearly average estimate of -$1.6. Based on analyst estimates, the high estimate for the next quarter is $0 and the low estimate is $0. The average estimate for the next quarter is thus $0.
